HR Execs on the Move

BenevolentAI

www.benevolent.com

 
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Christina Busmalis
Chief Revenue Officer Profile
Trecilla Lobo
Senior Vice President of People Profile

Similar Companies

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.

Orchestra BioMed

Orchestra BioMed is a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

Global Organization of EPA and DHA Omega-3s

We were founded in 2006 as GO3ETA, Inc., but do business as the Global Organization for EPA and DHA Omega-3s (GOED).� The roots of GOED go back to 2000 when the industry collaborated to petition the US Food and Drug Administration to establish a heart disease risk reduction claim for omega-3s.� The companies involved later formalized the relationship by forming the Omega-3 Working Group at the Council for Responsible Nutrition and collaborating again to develop what is now known as the GOED Voluntary Monograph. In 2006, when the Working Group was dissolved, twelve of the companies banded together to found GOED with a strong mandate to grow our membership to represent all sections of the EPA and DHA market. �

HTG Molecular Diagnostics

Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.